Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol

Current Vascular Pharmacology

Volumn 9, Issue 3, 2011, Pages 281-286

  Nordestgaard, Borge G ^a   Freiberg, Jacob J ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Apolipoproteins; Cardiovascular disease; Lipids; Lipoproteins; Non fasting; Postprandial; Remnant lipoproteins; Triglycerides

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; FAT TOLERANCE TEST; HEART INFARCTION; HUMAN; HYPERTRIGLYCERIDEMIA; POSTPRANDIAL STATE; RISK ASSESSMENT; RISK FACTOR; STANDARDIZATION;

CARDIOVASCULAR DISEASES; CHOLESTEROL; DIETARY FATS; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; POSTPRANDIAL PERIOD; RISK FACTORS; SEX FACTORS; TIME FACTORS; TRIGLYCERIDES;

EID: 79955583131     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016111795495585     Document Type: Article

References (42)

1. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007; 298: 299-308.
2. Cohn JS, McNamara JR, Cohn SD, Ordovas JM, Schaefer EJ. Postprandial plasma lipoprotein changes in human subjects of different ages. J Lipid Res 1988; 29: 469-79.
3. Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis DP, Cokkinos DV. Clinical relevance of postprandial lipaemia. Curr Med Chem 2005; 12: 1931-45.
4. Rifai N., Warnick GR. Lipids, lipoproteins, apolipoproteins, and other cardiovascular risk factors. In: Burtis CA, Ashwood ER, Bruns DE, eds. Tietz textbook of clinical chemistry and molecular diagnostics. 4 ed. Philadelphia: Elsevier Saunders; 2006. p. 903-82.
5. Graham I. European guidelines on cardiovascular disease prevention in clinical practice: Executive summary. Atherosclerosis 2007; 194: 1-45.
6. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-421.
7. Langsted A, Freiberg JJ, Nordestgaard BG. Fasting and non-fasting lipid levels: influence of normal food intake on lipids, lipoproteins, apolipoproteins, and cardiovascular risk prediction. Circulation 2008; 118: 2047-56.
8. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with non-fasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation 2008; 118: 993-1001.
9. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with non-fasting triglycerides and risk of cardiovascular events in women. JAMA 2007; 298: 309-16.
10. Freiberg JJ, Tybjaerg-Hansen A, Jensen JS, Nordestgaard BG. Non-fasting triglycerides and risk of ischemic stroke in the general population. JAMA 2008; 300: 2142-52.
11. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-85.
12. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995; 41: 153-8.
13. Kolovou GD, Mikhailidis DP, Nordestgaard B, Bilianou H, Panotopoulos G. Definition of postprandial lipemia. Curr Vasc Pharmacol 2011; 9: 292-301.
14. Ooi TC, Nordestgaard BG. Methods to study postprandial lipemia. Curr Vasc Pharmacol 2011; 9: 302-8.
15. Ooi TC, Robinson L, Graham T, Kolovou GD, Miklialidis DP, Lairon D. Proposing a "lipemic index" as a nutritional and research tool. Curr Vasc Pharmacol 2011; 9: 313-7.
16. Perez-Martinez P, Garcia-Rios A, Delgado-Lista J, Perez-Jimenez F, Lopez-Miranda J. Nutrigenetics of the postprandial lipoprotein metabolism: evidences from human intervention studies. Curr Vasc Pharmacol 2011; 9: 287-91.
17. Lairon D, Defoort C. Effects of nutrients on postprandial lipemia. Curr Vasc Pharmacol 2011; 9: 309-12.
18. Kolovou GD, Bilianou H, Mikhailidis DP. Postprandial Lipemia in Children and Adolescents. Curr Vasc Pharmacol 2011; 9: 318-20.
19. Mihas C, Kolovou GD, Mikhailidis DP, et al. Diagnostic value of postprandial triglyceride testing in healthy subjects: a metaanalysis. Curr Vasc Pharmacol 2011; 9: 271-80.
20. Kolovou GD, Mikhailidis DP, Kovar J, et al. Assessment and clinical relevance of postprandial triglycerides: an expert panel statement. Curr Vasc Pharmacol 2011; 9: 258-70.
21. Lipids. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Eds. The metabolic and molecular bases of inherited disease. 8th ed. New York, N.Y.: McGraw-Hill Inc.; 2010. p. 2705-960.
22. Brunzell JD, Deeb SS. Familial lipoprotein Lipase Deficiency, Apo C-II Defiency, and Hepatic Lipase Deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic & Molecular Bases of Inherited Disease. 8 ed. McGraw-Hill; 2001. p. 2789-816.
23. Nordestgaard BG, Nielsen LB. Atherosclerosis and arterial influx of lipoproteins. Curr Opin Lipidol 1994; 5: 252-7.
24. Nordestgaard BG. The vascular endothelial barrier--selective retention of lipoproteins. Curr Opin Lipidol 1996; 7: 269-73.
25. Stender S, Zilversmit DB. Transfer of plasma lipoprotein components and of plasma proteins into aortas of cholesterol-fed rabbits. Molecular size as a determinant of plasma lipoprotein influx. Arteriosclerosis 1981; 1: 38-49.
26. Shaikh M, Wootton R, Nordestgaard BG, et al. Quantitative studies of transfer in vivo of low density, Sf 12-60, and Sf 60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thromb 1991; 11: 569-77.
27. Nordestgaard BG, Tybjaerg-Hansen A, Lewis B. Influx in vivo of low density, intermediate density, and very low density lipoproteins into aortic intimas of genetically hyperlipidemic rabbits. Roles of plasma concentrations, extent of aortic lesion, and lipoprotein particle size as determinants. Arterioscler Thromb 1992; 12: 6-18.
28. Nielsen LB, Stender S, Jauhiainen M, Nordestgaard BG. Preferential influx and decreased fractional loss of lipoprotein(a) in atherosclerotic compared with non-lesioned rabbit aorta. J Clin Invest 1996; 98: 563-71.
29. Nielsen LB, Gronholdt ML, Schroeder TV, Stender S, Nordestgaard BG. In vivo transfer of lipoprotein(a) into human atherosclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 1997; 17: 905-11.
30. Nordestgaard BG, Stender S, Kjeldsen K. Reduced atherogenesis in cholesterol-fed diabetic rabbits. Giant lipoproteins do not enter the arterial wall. Arteriosclerosis 1988; 8: 421-8.
31. Nordestgaard BG, Zilversmit DB. Large lipoproteins are excluded from the arterial wall in diabetic cholesterol-fed rabbits. J Lipid Res 1988; 29: 1491-500.
32. Nordestgaard BG, Hjelms E, Stender S, Kjeldsen K. Different efflux pathways for high and low density lipoproteins from porcine aortic intima. Arteriosclerosis 1990; 10: 477-85.
33. Nordestgaard BG, Wootton R, Lewis B. Selective retention of VLDL, IDL, and LDL in the arterial intima of genetically hyperlipidemic rabbits in vivo. Molecular size as a determinant of fractional loss from the intima-inner media. Arterioscler Thromb Vasc Biol 1995; 15: 534-42.
34. Rutledge JC, Mullick AE, Gardner G, Goldberg IJ. Direct visualization of lipid deposition and reverse lipid transport in a perfused artery: roles of VLDL and HDL. Circ Res 2000; 86: 768-73.
35. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)-and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002; 13: 461-70.
36. Nordestgaard BG, Langsted A, Freiberg JJ. Non-fasting hyperlipidemia and cardiovascular disease. Curr Drug Targets 2009; 10: 328-35.
37. Eldrup N, Sillesen H, Prescott E, Nordestgaard BG. Ankle brachial index, C-reactive protein, and central augmentation index to identify individuals with severe atherosclerosis. Eur Heart J 2006; 27: 316-22.
38. Di AE, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302: 1993-2000.
39. Austin MA. Plasma triglyceride and coronary heart disease. Arterioscler Thromb 1991; 11: 2-14.
40. Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996; 3: 213-9.
41. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007; 115: 450-8.
42. Benlian P, De Gennes JL, Foubert L, Zhang H, Gagne SE, Hayden M. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. N Engl J Med 1996; 335: 848-54.